Dasatinib increases endothelial permeability leading to pleural effusion

Abstract

Pleural effusion is a frequent side effect of dasatinib, a second generation BCR-ABL tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukaemia. However, the underlying mechanisms remain unknown. We hypothesized that dasatinib alters endothelial integrity, resulting in increased pulmonary vascular endothelial permeability and pleural effusion. To test this, we established the first animal model of dasatinib-related pleural effusion, by treating rats with a daily regimen of high doses of dasatinib (10 mg/kg/day for 8 weeks). Pleural ultrasonography revealed that rats chronically treated with dasatinib developed pleural effusion after 5 weeks. Consistent with these in vivo observations, dasatinib led to a rapid and reversible increase in paracellular permeability of human pulmonary endothelial cell monolayers as reflected by increased macromolecule passage, loss of VE-cadherin and ZO-1 from cell-cell junctions, and development of actin stress fibers. These results were replicated using HUVECs and confirmed by decreased endothelial resistance. Interestingly, we demonstrated that this increased endothelial permeability is a reactive oxygen species (ROS) dependent mechanism in vitro and in vivo using a co-treatment with an anti-oxidant agent, N-acetyl cysteine (NAC). This study shows that dasatinib alters pulmonary endothelial permeability in a ROS-dependent manner in vitro and in vivo leading to pleural effusion.